J Psychoactive Drugs. 2014 Jan-Mar;46(1):27-36. doi: 10.1080/02791072.2014.877321.
This article describes the teenage vision of the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS) that humanity's future would be aided by the therapeutic and spiritual potential of psychedelic substances. The article traces the trajectory of MAPS from inception in 1986 to its present, noting future goals with respect to research, outreach, and harm reduction. MAPS was created as a non-profit psychedelic pharmaceutical company in response to the 1985 scheduling of 3,4-methylenedioxymethamphetamine (MDMA). Overcoming many hurdles, MAPS developed the first double-blind, placebo-controlled trial of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) and plans for FDA prescription approval in 2021. MAPS' program of research expanded to include a trial of lysergic acid diethylamide (LSD)-assisted psychotherapy for anxiety when facing life-threatening illness, observational studies of ibogaine in the treatment of addiction, and studies of MDMA for social anxiety in people with autism spectrum disorders. MAPS meets the challenges of drug development through a clinical research team led by a former Novartis drug development professional experienced in the conduct, monitoring, and analysis of clinical trials. MAPS' harm-reduction efforts are intended to avoid backlash and build a post-prohibition world by assisting non-medical users to transform difficult psychedelic experiences into opportunities for growth.
本文描述了迷幻药物多学科研究协会（MAPS）创始人的青少年愿景，即人类的未来将受益于迷幻药物的治疗和精神潜力。本文追溯了 MAPS 从 1986 年成立到现在的轨迹，指出了未来在研究、外展和减少伤害方面的目标。MAPS 作为一家非营利性迷幻药物制药公司成立，是为了应对 1985 年将 3,4-亚甲二氧基甲基苯丙胺（MDMA）列入附表的情况。克服了许多障碍，MAPS 开发了首例 MDMA 辅助心理治疗创伤后应激障碍（PTSD）的双盲、安慰剂对照试验，并计划在 2021 年获得 FDA 处方批准。MAPS 的研究计划扩大到包括一项在面临危及生命的疾病时使用麦角酸二乙酰胺（LSD）辅助心理治疗焦虑的试验、观察伊博加因治疗成瘾的研究，以及在自闭症谱系障碍患者中使用 MDMA 治疗社交焦虑的研究。MAPS 通过由一位前诺华药物开发专业人士领导的临床研究团队来应对药物开发的挑战，该专业人士在临床试验的进行、监测和分析方面具有丰富经验。MAPS 的减少伤害工作旨在通过帮助非医疗用途者将困难的迷幻体验转化为成长机会，避免反弹并建立一个禁毒后的世界。
